234 related articles for article (PubMed ID: 8899847)
1. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen L; Shen B; Wang S; Yu Y; Yan H; Shi Y; Duan G; Xiang P
Drug Test Anal; 2019 Jun; 11(6):898-905. PubMed ID: 30614204
[TBL] [Abstract][Full Text] [Related]
4. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
[TBL] [Abstract][Full Text] [Related]
5. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
[TBL] [Abstract][Full Text] [Related]
6. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Rohatagi S; Barrett JS; DeWitt KE; Lessard D; Morales RJ
Biopharm Drug Dispos; 1997 Nov; 18(8):665-80. PubMed ID: 9373724
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of two selegiline hydrochloride tablet products.
Müller FO; Schall R; Hundt HK; Joubert A; Middle MV; Muir AR; Duursema L; Groenewoud G; Swart KJ
Arzneimittelforschung; 1996 Nov; 46(11):1037-40. PubMed ID: 8955861
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
[TBL] [Abstract][Full Text] [Related]
10. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride).
Barrett JS; Rohatagi S; DeWitt KE; Morales RJ; DiSanto AR
Am J Ther; 1996 Apr; 3(4):298-313. PubMed ID: 11862265
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; DiSanto AR
Am J Ther; 1996 Oct; 3(10):688-98. PubMed ID: 11862224
[TBL] [Abstract][Full Text] [Related]
14. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.
Harder S; Fuhr U; Beermann D; Staib AH
Br J Clin Pharmacol; 1990 Jul; 30(1):35-9. PubMed ID: 2390430
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal absorption of pravastatin in healthy subjects.
Triscari J; O'Donnell D; Zinny M; Pan HY
J Clin Pharmacol; 1995 Feb; 35(2):142-4. PubMed ID: 7751423
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 and phase 2 metabolic activities along the small intestine in adult male sheep.
Maté L; Virkel G; Lifschitz A; Sallovitz J; Ballent M; Lanusse C
J Vet Pharmacol Ther; 2010 Dec; 33(6):537-45. PubMed ID: 21062305
[TBL] [Abstract][Full Text] [Related]
19. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers.
Petri N; Borga O; Nyberg L; Hedeland M; Bondesson U; Lennernas H
Int J Clin Pharmacol Ther; 2006 Feb; 44(2):71-9. PubMed ID: 16502766
[TBL] [Abstract][Full Text] [Related]
20. Risedronate gastrointestinal absorption is independent of site and rate of administration.
Mitchell DY; Eusebio RA; Dunlap LE; Pallone KA; Nesbitt JD; Russell DA; Clay ME; Bekker PJ
Pharm Res; 1998 Feb; 15(2):228-32. PubMed ID: 9523308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
